At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01672 ASCLETIS-B
Trading 01-19 15:51:58
12.850
-0.530
-3.96%
High13.140Low12.730Vol1.11M
Open13.140D1 Closing13.380Amplitude3.06%
Mkt Cap12.75BTradable Cap12.75BTotal Shares992.00M
T/O14.33MT/O Rate0.11%Tradable Shares992.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Why Ascletis Pharma (SEHK:1672) Is Up 6.3% After FDA Clears ASC30 Diabetes Trial And Obesity Data
Simply Wall St.  ·  01-16 20:29
Why Ascletis Pharma (SEHK:1672) Is Up 6.3% After FDA Clears ASC30 Diabetes Trial And Obesity Data
Hong Kong Stock Anomaly | Ascletis Pharma-B (01672) Surges Over 6% in Afternoon Trading on Strong ASC30 Data, Company Raises Buyback Cap to HK$500 Million
Stock News  ·  01-14
Hong Kong Stock Anomaly | Ascletis Pharma-B (01672) Surges Over 6% in Afternoon Trading on Strong ASC30 Data, Company Raises Buyback Cap to HK$500 Million
Ascletis Pharma (SEHK:1672) Is Up 9.9% After FDA Clears ASC30 Phase II Diabetes Trial - What's Changed
Simply Wall St.  ·  01-09
Ascletis Pharma (SEHK:1672) Is Up 9.9% After FDA Clears ASC30 Phase II Diabetes Trial - What's Changed
Hong Kong Stocks Close Mixed; Ascletis Pharma Receives U.S. Nod to Begin Phase II Trial of ASC30
MT Newswires Live  ·  01-05
Hong Kong Stocks Close Mixed; Ascletis Pharma Receives U.S. Nod to Begin Phase II Trial of ASC30
BRIEF-Ascletis Pharma Receives FDA IND Clearance For ASC30 Phase II Study
Reuters  ·  01-05
BRIEF-Ascletis Pharma Receives FDA IND Clearance For ASC30 Phase II Study
ASCLETIS-B (01672) Announces FDA Approval of IND for 13-Week Phase II Study of ASC30 in Diabetic Subjects
Stock News  ·  01-05
ASCLETIS-B (01672) Announces FDA Approval of IND for 13-Week Phase II Study of ASC30 in Diabetic Subjects
Ascletis Pharma Inc - Receives FDA Ind Clearance for Asc30 Phase Ii Study
THOMSON REUTERS  ·  01-05
Ascletis Pharma Inc - Receives FDA Ind Clearance for Asc30 Phase Ii Study
Ascletis Pharma Wins FDA IND Clearance for Phase II Diabetes Study
Reuters  ·  01-05
Ascletis Pharma Wins FDA IND Clearance for Phase II Diabetes Study
Zhixiang Hong Kong Stock Repurchase Statistics | January 1
Stock News  ·  01-01
Zhixiang Hong Kong Stock Repurchase Statistics | January 1
Ascletis-B (01672) Repurchases 200,000 Shares for HK$2.4829 Million on December 29
Stock News  ·  2025-12-29
Ascletis-B (01672) Repurchases 200,000 Shares for HK$2.4829 Million on December 29
Ascletis Pharma Repurchases 200,000 Shares for HK$2.48 Million in HKEX Filing
Reuters  ·  2025-12-29
Ascletis Pharma Repurchases 200,000 Shares for HK$2.48 Million in HKEX Filing
Orient Securities Initiates Coverage on Ascletis Pharma-B (01672) with "Buy" Rating, Sets Target Price at HK$18.38
Stock News  ·  2025-12-29
Orient Securities Initiates Coverage on Ascletis Pharma-B (01672) with "Buy" Rating, Sets Target Price at HK$18.38
Ascletis Pharma Files HKEX Disclosure on Repurchase of 100,000 Shares at HKD 1,254,850
Reuters  ·  2025-12-24
Ascletis Pharma Files HKEX Disclosure on Repurchase of 100,000 Shares at HKD 1,254,850
HK Stock Buyback Summary | Dec 24
Stock News  ·  2025-12-24
HK Stock Buyback Summary | Dec 24
ASCLETIS-B (01672) Repurchases 200,000 Shares for HK$2.49 Million on December 22
Stock News  ·  2025-12-22
ASCLETIS-B (01672) Repurchases 200,000 Shares for HK$2.49 Million on December 22
Ascletis Pharma Repurchases 200,000 Shares for HKD 2.56 Million in HKEX Filing
Reuters  ·  2025-12-19
Ascletis Pharma Repurchases 200,000 Shares for HKD 2.56 Million in HKEX Filing
Do Ascletis Pharma’s (SEHK:1672) ASC50 Phase I Results Hint At A Scalable Autoimmune Strategy?
Simply Wall St.  ·  2025-12-19
Do Ascletis Pharma’s (SEHK:1672) ASC50 Phase I Results Hint At A Scalable Autoimmune Strategy?
HK Stock Buyback Summary | December 18
Stock News  ·  2025-12-18
HK Stock Buyback Summary | December 18
HKEX Share Buyback Summary | December 17
Stock News  ·  2025-12-17
HKEX Share Buyback Summary | December 17
ASCLETIS-B (01672) Repurchases 200,000 Shares for HK$2.6099 Million on December 16
Stock News  ·  2025-12-16
ASCLETIS-B (01672) Repurchases 200,000 Shares for HK$2.6099 Million on December 16

Introduction

Company Name.
ASCLETIS-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Ascletis Pharma Inc is an investment holding company mainly engaged in the research and development, production, and sales of pharmaceutical products. The Company focuses on viral diseases, non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC), and oncology. The Company's product pipeline includes ASC22 for chronic hepatitis B functional cure, ASC10 for respiratory syncytial virus (RSV), ASC22 for human immunodeficiency virus (HIV) functional cure, ASC10 and ASC11 for COVID-19, ASC41 for NASH, ASC42 for PBC, ASC61 for solid tumors, ASC40 for moderate and severe acne, and others. The Company conducts its business in the domestic and overseas markets.
Issue price:
--